Production (Stage)
Inhibrx Biosciences, Inc.
INBX
$14.39
$0.473.38%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -43.31M | -47.87M | -43.86M | 1.83B | -78.71M |
| Total Depreciation and Amortization | 675.00K | 689.00K | 760.00K | 476.00K | 360.00K |
| Total Amortization of Deferred Charges | 533.00K | 0.00 | 0.00 | 2.07M | 1.24M |
| Total Other Non-Cash Items | 2.88M | 3.45M | 3.46M | -1.95B | 6.86M |
| Change in Net Operating Assets | 3.32M | 4.00K | 9.36M | 39.60M | 7.20M |
| Cash from Operations | -35.90M | -43.72M | -30.28M | -80.09M | -63.05M |
| Capital Expenditure | -21.00K | -16.00K | -247.00K | -1.22M | -1.12M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -21.00K | -16.00K | -247.00K | -1.22M | -1.12M |
| Total Debt Issued | 99.97M | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 0.00 | 0.00 | 71.68M | 38.73M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -125.00K | -- | -- | -41.43M | -- |
| Cash from Financing | 99.84M | 0.00 | 0.00 | 30.25M | 38.73M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 63.92M | -43.74M | -30.53M | -51.06M | -25.44M |